Details

Autor(en) / Beteiligte

• Prado, MJ Rial
• Díaz, MA Rico
• Ceballos, A Cosgaya
• Herranz, J Cuesta

Titel

A New Rush Schedule for Cotrimoxazole Desensitization: A Report of 2 Cases

Ist Teil von

• Journal of investigational allergology & clinical immunology, 2018-01, Vol.28 (4), p.256

Ort / Verlag

Barcelona: Esmon Publicidad

Erscheinungsjahr

2018

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Trimethoprim-sulfamethoxazole (cotrimoxazole) is an effective drug for the treatment of infectious diseases caused by gram-positive bacteria, gram-negative bacteria, and protozoa that reduces the risk of opportunistic infection by Pneumocystis jiroveci. The prevalence of adverse reactions to cotrimoxazole ranges from 20% to 100% in certain populations, such as HIV-infected patients, while in healthy individuals the prevalence is normally between 5% and 8%. The 2 possible therapeutic approaches following confirmed diagnosis of adverse reactions to cotrimoxazole are withdrawal of the drug and desensitization. The first case involved a 67-year-old white woman with stage IIIA follicular lymphoma. Desensitization was performed using a new rush intravenous desensitization protocol based on the protocol of Gluckstein and Ruskin, with good tolerance. The second case involved a 26-year-old white woman who had undergone lung transplantation owing to cystic fibrosis. The doctors report a new rush schedule for intravenous desensitization that is safe and effective and allows for maintenance doses to be administered on alternate days.